What question did this study set out to answer?

April 10, 2026Open Access

A Network Meta-Analysis Comparing the Efficacy of Lenvatinib, Atezolizumab plus Bevacizumab, and Sorafenib in the Treatment of Unresectable Hepatocellular Carcinoma

Key Points

This analysis aims to compare the efficacy of lenvatinib, atezolizumab plus bevacizumab, and sorafenib in treating unresectable hepatocellular carcinoma.
Conducted a network meta-analysis of available studies
Assessed overall survival as the primary outcome
Calculated hazard ratios (HRs) for treatment comparisons
Utilized SUCRA rankings to evaluate clinical trends
Overall survival rates were similar across all treatments
Hazard ratios showed no statistically significant differences
SUCRA rankings indicated a trend favoring atezolizumab plus bevacizumab

Abstract

Atezolizumab plus bevacizumab, lenvatinib, and sorafenib demonstrated similar therapeutic efficacy based on overall survival. Although the hazard ratios (HRs) were not statistically significant, the SUCRA ranking suggested a clinical trend favoring atezolizumab plus bevacizumab.

Bookmark

View Full Paper

Cite This Study

Remitha et al. (Wed,) studied this question.

synapsesocial.com/papers/69d894ad6c1944d70ce059cf https://doi.org/https://doi.org/10.31557/apjcp.2026.27.4.1377

Bookmark

View Full Paper